CYTT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cyteir Therapeutics's book value per share for the quarter that ended in Sep. 2023 was $3.47.
During the past 12 months, Cyteir Therapeutics's average Book Value Per Share Growth Rate was -20.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Cyteir Therapeutics's current price is $3.01. Its book value per share for the quarter that ended in Sep. 2023 was $3.47. Hence, today's PB Ratio of Cyteir Therapeutics is 0.87.
During the past 4 years, the highest P/B Ratio of Cyteir Therapeutics was 3.95. The lowest was 0.00. And the median was 0.00.
The historical data trend for Cyteir Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Book Value per Share | -1.46 | -1.39 | 5.32 | 4.12 |
Cyteir Therapeutics Quarterly Data | ||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Book Value per Share | Get a 7-Day Free Trial | 4.36 | 4.12 | 3.79 | 3.55 | 3.47 |
For the Biotechnology subindustry, Cyteir Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's PB Ratio falls into.
Cyteir Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (146.29 | - | 0.00) | / | 35.52 | |
= | 4.12 |
Cyteir Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (125.03 | - | 0.00) | / | 36.08 | |
= | 3.47 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Cyteir Therapeutics (OTCPK:CYTT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Cyteir Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
John F Thero | director | C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
Adam M Veness | officer: General Counsel | C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Stephen H. Sands | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Jeffrey Humphrey | director | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Droia Invest Ii Scsp | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Janwillem Naesens | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Sa Ihl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Karen Hong | director | 69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
Bv Wepaven | 10 percent owner | BRUSSELSESTEENWEG 11, MEISE C9 1860 |
Luc Verelst | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Df Ii Gp Sarl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Timothy Romberger | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Racquel Bracken | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire Business Wire • 11-01-2021
By Business Wire Business Wire • 02-08-2022
By Business Wire Business Wire • 01-12-2022
By Business Wire Business Wire • 11-12-2021
By Business Wire Business Wire • 05-05-2022
By Business Wire • 10-12-2023
By Business Wire Business Wire • 04-18-2022
By Business Wire Business Wire • 05-10-2023
By Business Wire Business Wire • 09-20-2021
By Business Wire Business Wire • 08-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.